Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Renalytix shares jump on draft US Medicare coverage decision
(Sharecast News) - Renalytix shares were rocketing on Friday morning, after it announced that the Centers for Medicare and Medicaid Services (CMS) in the US had published a draft local coverage determination (LCD) for its 'KidneyIntelX' and 'kidneyintelX.dkd' testing products, outlining the coverage and pricing for the tests. The AIM-traded firm said that according to the draft LCD, the established Medicare price for KidneyIntelX and kidneyintelX.dkd would be $950 per test.
Distinct common procedural terminology (CPT) codes, used in the US healthcare system for common billing across providers, had been set for each test and were available in the CMS 2024 clinical lab fee schedule.
The company said the draft LCD specified coverage for the use of KidneyIntelX or kidneyintelX.dkd for patients with diagnosed type-2 diabetes and stage 1 to 3b chronic kidney disease as reasonable and necessary.
Any limitations specified in the draft LCD aligned with the US Food and Drug Administration (FDA) label for kidneyintelX.dkd, it noted.
National Government Services (NGS), a subsidiary of Elevance Health, submitted the LCD.
NGS serves as a Medicare administrative contractor with CMS, responsible for claim review and payment for testing conducted in Renalytix's New York City laboratory.
A 45-day public comment period started on 8 February, and would end on 23 March.
Renalytix formally requested an LCD from NGS and provided substantial peer-reviewed published evidence supporting the coverage of KidneyIntelX and kidneyintelX.dkd.
NGS conducted a contractor advisory committee meeting on 29 August 2023, where a panel of external experts reviewed and discussed the clinical evidence.
Renalytix said it believed that, based on that evidence and the FDA's de Novo marketing authorisation for the kidneyintelX.dkd test, there was a strong basis for NGS to determine the tests as reasonable and necessary for Medicare beneficiaries.
Following the open public meeting, NGS would review public comments and issue a final LCD, expected within 2024.
At 1012 GMT, shares in Renalytix were up 30.54% at 13.38p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.